Loading...
9th Antibody Industrial Symposium 2021 June 22 - 25 2021 | DIGITAL
News Twitter

PROGRAMME

schedule & speakers

Day 1

Tuesday, June 22nd 2021

9h00

Welcome address

9h15

OPENING KEYNOTES LECTURES

10h15

Track New Engineering Approaches for the Next-generation of Therapeutic Antibodies and Alternative Fusion Formats

Session I

Therapeutic antibody engineering to improve drugability
GenScript ProBio, China Li Chen

Li Chen
Associate Director of Biologics Discovery
GenScript ProBio, China

Lava Therapeutics Paul Parren

Paul Parren
Executive VP and Head of R&D
Lava Therapeutics, Netherlands

Inserm Pierre Martineau

Pierre Martineau
Team Leader
Functional Screening and Targeting in Cancer Unit, Inserm
Deputy Director
Institut de Recherche en Cancérologie de Montpellier (IRCM), Université de Montpellier
Founder
Mabqi, France

HexElect technology: mutually dependent therapeutic IgG antibody combinations that act as Bio-Logic AND gates
Genmab Rob de Jong

Rob de Jong
Director, Antibody Format Development Lead
Genmab, Netherlands

Track Adoptive Cell Therapy : Latest Advancements

Session I

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain Sonia Guegan

Sonia Guegan
Junior Investigator
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

12h00

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track New Engineering Approaches for the Next-generation of Therapeutic Antibodies and Alternative Fusion Formats

Session II

NK cell engagers
Innate Pharma, France Eric Vivier

Eric Vivier
Professor of Immunology
Aix-Marseille University & Public Hospital of Marseille, France
Scientific Director
Innate Pharma, France

Affinity-optimization of B7H6 for NK cell redirection
Merck KGaA, Germany Stefan Zielonka

Stefan Zielonka
Associate Director, Protein Engineering & Antibody Technologies
Merck KGaA, Germany

Immunotherapy Drug Development characterization tools: From reporter assays to primary cell-based approaches and immunoassays
Promega Bénédicte Gagny

Bénédicte Gagny
Product Manager, Cell-Based Assay, Proteomic and tools for biologics characterization
Promega, France

Track Adoptive Cell Therapy : Latest Advancements

Session II

16h00

Pitch Session : Innovative Approaches to detect and fight Diseases

Call for Abstracts ends April 30th 2021

Track Enhancing Immunotherapy Efficacy and Safety : New Preclinical Models

Retrogenix Limited, UK Diogo Rodrigues Ferreirinha

Diogo Rodrigues Ferreirinha
European Business Development Manager
Retrogenix Limited, UK

IRCCS San Raffaele Scientific Institut, Italy Monica Casucci

Monica Casucci
Group Leader, Innovative Immunotherapies Unit
IRCCS San Raffaele Scientific Institut, Italy

Novel Organoid Models for Drug Development
Hubrecht Organoid Technology (HUB), Netherlands Robert Vries

Robert Vries
CEO
Hubrecht Organoid Technology (HUB), Netherlands

Exploring the 3D-3-culture models to dissect tumour-macrophage crosstalk
iBET Catarina Brito

Catarina Brito
Head of the Advanced Cell Models Laboratory of the Animal Cell Technology Unit
iBET and ITQB-NOVA, Portugal

17h30

Partnering (B2B Virtual Meetings)

19h00

End of DAY 1

Day 2

Wednesday, June 23rd 2021

9h30

OPENING KEYNOTE LECTURE

Antibody–Drug Conjugates: The Last Decade
GICC, University of Tours, France Nicolas Joubert

Nicolas Joubert
Associate-Professor
GICC, University of Tours, France

10h15

Track New trends in ADCs Development

Mablink Warren Viricel

Warren Viricel
Chief Scientific Officer
Mablink, France

Centre Leon Berard, Inserm UA8, France Sandrine Valsesia-Wittmann

Sandrine Valsesia-Wittmann
Senior Scientist in immuno-oncology and combinations therapies
Centre Leon Berard, Inserm UA8, France

Track Artificial Intelligence Tools to accelerate Drug Discovery

Sanofi, France Hervé Minoux

Hervé Minoux
Associate Director of Data Science: in silico Drug Design
Sanofi, France

OSE Immunotherapeutics Nicolas Poirier

Nicolas Poirier
CSO
OSE Immunotherapeutics

12h00

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track Intellectual Property - Patenting antibodies : lessons learnt from recent court decisions

Session Sponsored by Regimbeau

Track mAbs against COVID-19 Pandemic

Development of polyclonal neutralizing antibodies against SARS-CoV-2
Xenothera, France Bernard Vanhove

Bernard Vanhove
CSO & COO
Xenothera, France

Monoclonal antibody blocking SARS-CoV-2 infection
University Utrecht, Netherlands Berend Jan Bosch

Berend Jan Bosch
Associate Professor
University Utrecht, Netherlands

Combined Single-cell Dispensing and 3D Full Well Imaging for Cell Lines with >99.99% Probability of Monoclonality
CYTENA Adrian Zambrano

Adrian Zambrano
Senior Field Application Specialist
CYTENA

16h00

Live Poster Session

Call for Abstracts ends April 30th 2021

Track Targeting the brain with biologics drugs

Targeting biologic drugs through the blood-brain barrier as IgG fusion proteins
UCLA, Los Angeles, CA, USA William M. Pardridge

William M. Pardridge, M.D
Distinguished Professor Emeritus
UCLA, Los Angeles, CA, USA

17h30

Announcement of Best Poster

17h40

Partnering (B2B Virtual Meetings)

19h00

End of DAY 2

Day 3

Thursday, June 24th 2021

9h30

OPENING KEYNOTE LECTURE

Sanquin Research, Netherlands Gestur Vidarsson

Gestur Vidarsson
Head of Immunoglobulin Research
Sanquin Research, Netherlands

10h15

Track Driving Innovative Drugs into Clinical Success

Session I

Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy
Heidelberg Pharma AG, Germany Andreas Pahl

Andreas Pahl
CSO
Heidelberg Pharma AG, Germany

Track Improving Developability & CMC of biotherapies

Session I

Full Characterisation of Biologics - Process Development and Optimization for Best Process Economics
SARTORIUS Helge Schnerr

Helge Schnerr
Global Marketing
SARTORIUS, Germany

How to Control Glycosylation using In Vitro Glycoengineering
Roche Mathieu Thomas

Mathieu Thomas
International Alliance Manager
Roche

Centre d’Immunologie Pierre Fabre, France Alain Beck

Alain Beck
Senior Director, Biologics CMC & developability
Centre d’Immunologie Pierre Fabre, France

Challenges of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs
Merck, Italy Horst Bierau

Horst Bierau
Senior Scientific Advisor – Head CMC Science & Intelligence
Merck, Italy

12h00

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track Driving Innovative Drugs into Clinical Success

Session II

Antibody-armed oncolytic viruses to address immuno-suppressed tumors
Transgene, France Eric Quéméneur

Eric Quéméneur
Executive vice-president, CSO
Transgene, France

ARIDIS Pharmaceutical, USA Vu L. Trong

Vu L. Trong
CEO
ARIDIS Pharmaceutical, USA

Accelerating Drug Discovery with Twist Biopharma
Twist Bioscience, USA Qiang Liu

Qiang Liu
Director of Antibody Engineering
Twist Bioscience, USA

Track Improving Developability & CMC of biotherapies

Session II

Université Paris-Saclay, UMR-S 996 -Inserm/UPSaclay, France Marc Pallardy

Marc Pallardy
Professor, Director of Research
Université Paris-Saclay, UMR-S 996 -Inserm/UPSaclay, France

Novel Solution For High Throughput Antibody And Protein Purification Using Magnetic Beads
GenScript USA Nishant Saxena

Nishant Saxena
Product Manager, Protein Purification
GenScript USA

16h00

Closing Keynote

Antibodies to watch in 2021: Mid-year update
The Antibody Society Janice Reichert

Janice Reichert
Editor-in-Chief
mAbs
Executive Director
The Antibody Society
Managing Director
Reichert Biotechnology Consulting LLC, USA

16h40

Announcement of AIS2022

16h50

Partnering (B2B Virtual Meetings)

19h00

End of DAY 3

Day 4

Friday, June 25th 2021

9h00

Partnering (B2B Virtual Meetings)

12h00

Lunch Break

14h00

Partnering (B2B Virtual Meetings)

19h00

End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)4 78 02 39 91
ana-sofia.antunes@mabdesign.fr